Literature DB >> 33191958

A click-ready pH-triggered phosphoramidate-based linker for controlled release of monomethyl auristatin E.

Feyisola P Olatunji1, Jacob W Herman1, Brittany N Kesic1, Damilola Olabode2, Clifford E Berkman1.   

Abstract

In this work, we developed a novel "click"-ready pH-cleavable phosphoramidate linker for controlled-release of monomethyl auristantin E (MMAE) in antibody- and small molecule-drug conjugates application. This water-soluble linker was found to have tremendous stability at physiological pHs while rapidly releasing its payload at acidic pH. The linker can also be tailored to release payloads of diverse functional groups, broadening its applications.

Entities:  

Keywords:  Cleavable linker; MMAE; Monomethyl auristatin E; Payload click-ready; Phosphoramidate

Year:  2020        PMID： 33191958      PMCID： PMC7665082          DOI： 10.1016/j.tetlet.2020.152398

Source DB:  PubMed          Journal:  Tetrahedron Lett        ISSN： 0040-4039            Impact factor:   2.415


  15 in total

Review 1.  Antibody-drug conjugates: basic concepts, examples and future perspectives.

Authors:  Giulio Casi; Dario Neri
Journal:  J Control Release       Date:  2012-01-28       Impact factor: 9.776

Review 2.  Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.

Authors:  Laurent Ducry; Bernhard Stump
Journal:  Bioconjug Chem       Date:  2010-01       Impact factor: 4.774

3.  Phosphoramidate derivates as controlled-release prodrugs of l-Dopa.

Authors:  Feyisola P Olatunji; Brittany N Kesic; Cindy J Choy; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2019-08-05       Impact factor: 2.823

Review 4.  Cleavable linkers in antibody-drug conjugates.

Authors:  Jonathan D Bargh; Albert Isidro-Llobet; Jeremy S Parker; David R Spring
Journal:  Chem Soc Rev       Date:  2019-08-12       Impact factor: 54.564

Review 5.  Antibody-drug conjugates for cancer.

Authors:  Cindy H Chau; Patricia S Steeg; William D Figg
Journal:  Lancet       Date:  2019-08-31       Impact factor: 79.321

6.  Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

Authors:  Philip R Hamann; Lois M Hinman; Irwin Hollander; Carl F Beyer; Delores Lindh; Ryan Holcomb; William Hallett; Hwei-Ru Tsou; Janis Upeslacis; Dan Shochat; Andrew Mountain; David A Flowers; Irwin Bernstein
Journal:  Bioconjug Chem       Date:  2002 Jan-Feb       Impact factor: 4.774

7.  Second-Generation Tunable pH-Sensitive Phosphoramidate-Based Linkers for Controlled Release.

Authors:  Cindy J Choy; Corinne R Ley; Austen L Davis; Brian S Backer; Jonathan J Geruntho; Brian H Clowers; Clifford E Berkman
Journal:  Bioconjug Chem       Date:  2016-09-02       Impact factor: 4.774

8.  Tunable pH-Sensitive Linker for Controlled Release.

Authors:  Cindy J Choy; Jonathan J Geruntho; Austen L Davis; Clifford E Berkman
Journal:  Bioconjug Chem       Date:  2016-03-02       Impact factor: 4.774

9.  Tunable pH-Sensitive 2-Carboxybenzyl Phosphoramidate Cleavable Linkers.

Authors:  Brian S Backer; Cindy J Choy; Austen L Davis; Zachery S Browne; Clifford E Berkman
Journal:  Tetrahedron Lett       Date:  2020-01-25       Impact factor: 2.415

10.  Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates.

Authors:  Thomas H Pillow; Jack D Sadowsky; Donglu Zhang; Shang-Fan Yu; Geoffrey Del Rosario; Keyang Xu; Jintang He; Sunil Bhakta; Rachana Ohri; Katherine R Kozak; Edward Ha; Jagath R Junutula; John A Flygare
Journal:  Chem Sci       Date:  2016-08-22       Impact factor: 9.825
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.